Markets

Onconova Therapeutics (ONTX) in Focus: Stock Up 14.0% - Tale of the Tape

Onconova Therapeutics, Inc. ( ONTX ) was a big mover last session with its shares rising just over 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock is has gained over 22% in the past five trading sessions.

This clinical-stage biopharmaceutical company has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate hasn't been in trend either. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Onconova Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.

Investors interested in the Med-Drugs industry may consider better-ranked stocks like Aeolus Pharmaceuticals Inc. ( AOLS ), Ariad Pharmaceuticals Inc. ( ARIA ) and Ohr Pharmaceutical, Inc. ( OHRP ). All the three stocks sport a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ONCONOVA THERAP (ONTX): Free Stock Analysis Report

AEOLUS PHARMACT (AOLS): Get Free Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

OHR PHARMACEUT (OHRP): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NBSE AOLS ONTX

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More